HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal

Amgen’s Prolia/Xgeva Original Sales Close To $100m, mAbxience In Phase III

 
• By Dean Rudge
  
South Korea flag
HK inno.N plans to seek approval "quickly" • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products